CD8A and neoplasm: Exosomes engineered to upload HPV-E7 fused with the Nefmut exosome-anchoring protein have been recently shown to efficiently elicit a CD8+ T-specific adaptive immune response against E7 [19].This immune response blocked the growth of tumor cells implanted after immunization, appearing however only partly efficient in the therapeutic setting.